Frankfurt - Delayed Quote EUR

Scandinavian ChemoTech AB (publ) (8V6.F)

0.1575 +0.0110 (+7.51%)
At close: April 26 at 9:15 AM GMT+2
Key Events
Loading Chart for 8V6.F
DELL
  • Previous Close 0.1465
  • Open 0.1445
  • Bid 0.1410 x --
  • Ask 0.2420 x --
  • Day's Range 0.1445 - 0.1575
  • 52 Week Range 0.0768 - 0.3950
  • Volume 5,000
  • Avg. Volume 0
  • Market Cap (intraday) 3.439M
  • Beta (5Y Monthly) 1.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses. The company markets its products through distribution channels and a network of human medicine opinion leaders in the Middle East, Asia, India, and Africa. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.

chemotech.se

6

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 8V6.F

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

8V6.F
10.00%
OMX Stockholm 30 Index
6.65%

1-Year Return

8V6.F
60.13%
OMX Stockholm 30 Index
13.72%

3-Year Return

8V6.F
90.57%
OMX Stockholm 30 Index
14.13%

5-Year Return

8V6.F
--
OMX Stockholm 30 Index
0.00%

Compare To: 8V6.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 8V6.F

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    3.49M

  • Enterprise Value

    3.42M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.85

  • Price/Book (mrq)

    2.78

  • Enterprise Value/Revenue

    1.21

  • Enterprise Value/EBITDA

    -0.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -69.17%

  • Return on Equity (ttm)

    -168.57%

  • Revenue (ttm)

    2.82M

  • Net Income Avi to Common (ttm)

    -21.09M

  • Diluted EPS (ttm)

    -0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    923k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -14.68M

Company Insights: 8V6.F